688198.SHG Beijing Balance Medical Technology Co Ltd
- Market cap
- CNY 10.0B
- P/E
- 55.9x
- P/B
- 8.25x
- ROE
- 8.7%
- Dividend yield
- 1.11%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688198.SHG undervalued?
Graham numberThe Graham number of Beijing Balance Medical Technology Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beijing Balance Medical Technology Co Ltd fundamental analysis
No fundamental analysis for Beijing Balance Medical Technology Co Ltd yet.
Beijing Balance Medical Technology Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beijing Balance Medical Technology Co Ltd
Beijing Balance Medical Technology Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of artificial bioprosthetic valve medical devices in China and internationally. It offers bovine pericardial, porcine aortic tissue, and limiting expandable artificial biological heart valves, as well as tricuspid annuloplasty ring for heart valve repair and treatment. The company also provides outflow tract single valve patch, pulmonary val…
Full company profileBeijing Balance Medical Technology Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Beijing Balance Medical Technology Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 78.5M | 92.3M | 111M | 146M | 182M | 252M | 295M | 371M | 502M | 620M | 553M |
| Gross Profit | 69.1M | 82.3M | 101M | 133M | 162M | 222M | 264M | 333M | 443M | 553M | 488M |
| Operating Income | 37.2M | 42.9M | 39.3M | 68.0M | 48.8M | 36.1M | 85.9M | 104M | 138M | 206M | 119M |
| EBITDA | - | 54.1M | 46.8M | 78.4M | 54.5M | 56.8M | 113M | 134M | 174M | 250M | 120M |
| Net Income | 31.2M | 42.2M | 33.4M | 63.1M | 56.5M | 51.2M | 95.1M | 115M | 146M | 194M | 102M |
| EPS | - | 0.59 | 0.46 | 0.66 | 0.42 | 0.38 | 0.70 | 0.84 | 1.07 | 1.41 | 0.74 |
| Balance Sheet | |||||||||||
| Total Assets | 124M | 147M | 210M | 788M | 871M | 1.03B | 1.18B | 1.33B | 1.43B | 1.62B | 1.55B |
| Total Liabilities | 29.7M | 13.0M | 14.0M | 23.4M | 35.6M | 42.7M | 80.2M | 138M | 180M | 310M | 394M |
| Shareholders' Equity | 94.0M | 134M | 197M | 766M | 837M | 990M | 1.10B | 1.19B | 1.25B | 1.33B | 1.17B |
| Cash & Short-term Investments | 47.6M | 79.4M | 146M | 718M | 150M | 157M | 128M | 295M | 56.0M | 39.7M | 54.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 45.1M | 46.4M | 53.9M | 63.9M | 50.8M | 76.5M | 129M | 141M | 136M | 198M | - |
| Capital Expenditure | 13.5M | 13.1M | 2.18M | 2.02M | 7.69M | 72.2M | 105M | 129M | 163M | 136M | 124M |
| Free Cash Flow | - | 33.3M | 51.7M | 61.9M | 43.1M | 4.27M | 24.0M | 12.5M | -27.0M | 61.6M | -69.7M |
| Ratios | |||||||||||
| ROE | 33.2% | 31.5% | 17.0% | 8.2% | 6.8% | 5.2% | 8.6% | 9.6% | 11.7% | 14.6% | 8.7% |
| ROA | 25.2% | 28.8% | 15.9% | 8.0% | 6.5% | 5.0% | 8.1% | 8.7% | 10.2% | 11.9% | 6.6% |
| Net Profit Margin | 39.7% | 45.7% | 30.2% | 43.2% | 31.1% | 20.3% | 32.2% | 31.1% | 29.2% | 31.2% | 18.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Beijing Balance Medical Technology Co Ltd dividends
- Dividend yield
- 1.11%
- Forward dividend
- 0.80 CNY
- Payout ratio
- 57.3%
- Ex-dividend date
- May 26, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 111M | 0.80 | 57.3% |
| 2024 | CNY 109M | 0.80 | 74.7% |
| 2023 | CNY 67.8M | 0.50 | 58.9% |
| 2022 | CNY 48.2M | 0.36 | 50.7% |
| 2021 | CNY 19.2M | 0.14 | 37.5% |
| 2020 | CNY 19.2M | 0.14 | 34.0% |
| 2019 | CNY 19.2M | 0.20 | 30.4% |
| 2018 | CNY 25.0M | 0.35 | 74.9% |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on May 26, 2022.
Who owns Beijing Balance Medical Technology Co Ltd
- Insiders 73.23%
- Institutions 8.02%
- Public & others 18.75%
- Shares outstanding 138M
- Free float 36.3M
Beijing Balance Medical Technology Co Ltd company profile
- Company name
- Beijing Balance Medical Technology Co Ltd
- Ticker
- 688198.SHG
- ISIN
- CNE100005X15
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 746
- Fiscal year end
- December
- Address
- No. 2 Huachang Road, Beijing, China, 102200
- Phone
- 86 10 6073 5920
- Website
- balancemed.cn
About Beijing Balance Medical Technology Co Ltd
Beijing Balance Medical Technology Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of artificial bioprosthetic valve medical devices in China and internationally. It offers bovine pericardial, porcine aortic tissue, and limiting expandable artificial biological heart valves, as well as tricuspid annuloplasty ring for heart valve repair and treatment. The company also provides outflow tract single valve patch, pulmonary valved conduit, cardiothoracic biopatch, thoracic surgery biological patch, and dacron patch, as well as ventricular septal defect occluder, PDA occluder, ASD occluder, and cardiovascular occluder delivery system for congenital heart disease treatment. In addition, it offers neurosurgery microvascular pressure relief gasket, neurosurgical biopatch, and biological hernia patch for soft tissue repair. The company was founded in 2001 and is headquartered in Beijing, China.
Beijing Balance Medical Technology Co Ltd management
6- Dr. Lei JinChairman of the Board & GM · born 1954
- Ms. Qi ChengFinancial Director & Director · born 1968
- Ms. Liyan LiDeputy GM & Director · born 1980
- Mr. Wuping LiDeputy GM & Director · born 1978
- Tao ZhangAccounting Supervisor
- Ms. Xiaozhou GuanBoard Secretary · born 1984